SCHEMBL12787337

SCHEMBL12787337

Cc1cc(C)c2c(c1)oc(=O)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.41
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
PKM P14618 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
KMT2A Q03164 4/20 0.37
KDM4E B2RXH2 1/20 0.37
PON1 P27169 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
MEN1 O00255 1/20 0.34
MIF P14174 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10187968 0.85 ACACB (0.39) ACACBPKMKMT2AKDM4EMEN1
SCHEMBL1285780 0.81 ALDH1A1 (0.41) ACACBCA1CA9CA12PKM
SCHEMBL1286093 0.81 KDR (0.44) ACACBCA9CA12PKMKMT2A
SCHEMBL1285654 0.81 ACACB (0.39) ACACBPKMKMT2AKDM4EMEN1
SCHEMBL29951002 0.78 ACACB (0.40) ACACBPKMKMT2AKDM4EMEN1
SCHEMBL4064262 0.78 ALDH1A1 (0.44) ACACBPKMKMT2AKDM4EESR1
SCHEMBL12157655 0.77 MIF (0.40) PKMSMN1; SMN2KMT2AKDM4EPON1
SCHEMBL16435008 0.75 ACACB (0.43) ACACBCA1CA9CA12PKM
SCHEMBL4064265 0.74 ACACB (0.40) ACACBCA1CA9CA12CA2
SCHEMBL16362388 0.74 MAOB (0.40) ACACBCA1CA9CA12PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629137-B2 CGRP antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-14 US disclosed
US-20130029975-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20110059954-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-10 US disclosed
US-20070099903-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059954-A1 CGRP ANTAGONISTS CALCRL, CALCR, CALCA ACACB 4868/4885CA1 2123/4885CA9 1750/4885
US-20070099903-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA ACACB 4871/4885CA1 1807/4885CA9 2434/4885
US-20130029975-A1 CGRP ANTAGONISTS CALCRL, CALCR, CALCA ACACB 4868/4885CA1 2123/4885CA9 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.